chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Sweating), CHILLS (chills), MYALGIA (Body Aches) and NAUSEA (Nausea) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 02YM20A) for COVID-19 vaccination. The patient's past medical history included No adverse reaction. On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Apr-2021, the patient experienced HYPERHIDROSIS (Sweating), CHILLS (chills), MYALGIA (Body Aches) and NAUSEA (Nausea). At the time of the report, HYPERHIDROSIS (Sweating), CHILLS (chills), MYALGIA (Body Aches) and NAUSEA (Nausea) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route), the reporter did not provide any causality assessments. Concomitant product is not provided. Treatment is not provided.
Pain at injection site. 24hrs after injection site, my left arm started hurting and painful to the touch. At 48 hours, the injection site is very raised and red. It's approximately 3inches long by 2inches wide. It's very sensitive to the touch and very hot.  I went back to the medical clinic and was told to draw a circle around the site, and watch for further spreading, apply an ice pack, and submit this reaction to Vaers.
Very nauseous/dizzy, migraine, on the day after. Swelling in lymph nodes on left arm (injection arm)
3/5/2021 - 3:00 p.m. -  forward - Fatigue 3/8/2021 - Fatigue - All day
36 to 48 hrs p/vax pt began a high pitched cry lasting over 4 hrs;; also began convulsive movements; arched back, threw head back, shook hands; fever-low grade; on APAP; no treatment;
Rash on the contralateral arm, pruritis, now with blistering.  Spreading rash. No other current symptoms.
This spontaneous report was received from a certified medical assistant refers to a multiple unspecified patients of unknown age and gender. The patient's medical history, concurrent conditions, drug reactions or allergies were not reported. On an unknown dates, the patients were vaccinated with an improperly stored doses of MMR II, lot number K018965, expiration date 15-OCT-2016, (dose and route were not reported). There was no concomitant medication reported. No adverse effect was reported. No product quality complaint was involved. It was unknown if the patients sought medical attention. This is one of several reports from the same source. Additional information has been requested.
Large local reaction, shoulder possible cellulitis. 9x8 cm red, hot raised area at injection site.
cyanosis of fingertips of lt hand (mild;BP 80/50, P54, R24;this is a transfer from state of montana;23JAN98 was pt first day of class;
Day 1 (8/21) was sore arm only. Day 2 (8/22) after vax more sore than day before. 8/27- arm pit on injected arm swollen lymph node. 8/28- bigger lymph node and headache all day. 8/29- not sleeping well, bigger lymph node, headache all day. 8/30-not sleeping well, bigger lymph node, headache all day. 8/31-not sleeping well, bigger lymph node, headache all day and injection site is red/hot/hard and has little raised bumps.
Pt called and reported that yesterday she took her 2nd dose of Moderna at Facility and last night she started to feel body aches, HA and sore throat.  At one point she reported that "her throat felt so swollen that she felt it was hard to breath but her husband gave him an allergy medication and she felt better".  The next day, pt reported feeling better and she continues to take allergy meds.
Information has been received from a physician concerning a 22 year old female patient who on 28-OCT-2010 was vaccinated with a dose of GARDASIL (lot # and expire date not reported), intramuscularly. On 28-OCT-2010, after the patient received her GARDASIL vaccine, she had an episode of syncope and when she fell, she busted her lip. The patient did not seek medical attention. On 28-OCT-2010, the patient recovered. Additional information has been requested.
At about 2 PM on Tuesday, 1/26/21, just below my injection site, my arm began to get itchy, swollen, and hot. Even without scratching it, it has a slight red tinge to it. The affected area is about 1/3 of my upper arm. This has persisted for the past day. The symptoms have lessened, but not fully resolved, this morning.  I have applied regular body lotion as well as some tea tree oil to the affected area.   I have sent a message to my primary care physician, but I have not sought medical care otherwise. I have reported this to my facility's COVID vaccine clinic.
At 8:10 am Thursday started with a fever and swelling of my lymph nodes under my arm on the injection side, left, and just not felling well. By 2:30 pm on Thursday had high fever, muscle, bone and joint pain, weakness, chills and sweats. Pain in my swollen lymph nodes under arm. Fever broke Friday at 9 am still experiencing pain in lymph nodes, some sweating, generalized tiredness and over all just not feeling well.
Hot and cold sweats for days. Developed a cough with light wheezing - lungs were clear upon additional appointment. Hives on both legs.
Heart arrhythmia; Blood Pressure went up to as high as 230-220 over 160-130.; This spontaneous case was reported by a consumer and describes the occurrence of ARRHYTHMIA (Heart arrhythmia) and HYPERTENSIVE CRISIS (Blood Pressure went up to as high as 230-220 over 160-130.) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No relevant medical history reported.  Concomitant products included LOSARTAN, METOPROLOL, SOTALOL, POTASSIUM CHLORIDE (KLOR-CON), APIXABAN (ELIQUIS) and FUROSEMIDE for an unknown indication.   On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Apr-2021, the patient experienced ARRHYTHMIA (Heart arrhythmia) (seriousness criterion medically significant) and HYPERTENSIVE CRISIS (Blood Pressure went up to as high as 230-220 over 160-130.) (seriousness criterion medically significant). At the time of the report, ARRHYTHMIA (Heart arrhythmia) outcome was unknown and HYPERTENSIVE CRISIS (Blood Pressure went up to as high as 230-220 over 160-130.) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 18-Apr-2021, Blood pressure measurement: 220-230 over 130-160 (High) 220-230 over 130-160 and 111/60 (Inconclusive) 111/60. On 18-Apr-2021, Electrocardiogram ambulatory: abnormal (abnormal) showed premature ventricular contractions.         Patient reported that his usual blood pressure was around 140/78-84". His doctor advised him to go to the hospital. He was given clonidine in the ER and his blood pressure dropped to 111/60. The caller was also hooked to a Holter monitor and it showed PVC. Once the blood pressure went down, he was sent home.  The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the mRNA-1273 in response to the events was not applicable.  Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Pt was administered Pfizer vaccine on 5/20 when the patient was administered Moderna for dose #1 on 4/22.  NO adverse reactions noted.
A physician reported that a 16 month old male received his fourth dose of Prevnar vaccine on 12/27/02. He subsequently developed streptococci pneumoniae and was hospitalized. The child previously received three doses of Prevnar. No further information was available at the date of this report.
28 minutes after accination, SOB mild dizziness with tachycardia. resolved after 15-20 min lying down.
severe allergic reaction; This is a spontaneous report from a contactable consumer (patient).   A patient of unspecified age and gender received second dose of bnt162b2 (BNT162B2), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 2ND DOSE, SINGLE for covid-19 immunisation.  The patient medical history was not reported. Concomitant medication included dupilumab (DUPIXENT) taken for an unspecified indication, start and stop date were not reported.  The patient experienced severe allergic reaction about 2 weeks after receiving second dose. The event was assessed as medically significant on an unspecified date with outcome of unknown.   Information on batch number has been requested.
100.4 Fever fro 24 hours , Teeth chattering, body aches, head aches, jittery feeling
This spontaneous report as received from a nurse refers to an unspecified number of patients of unknown demographics. No concurrent conditions or medical history were provided. On an unknown date, those patients were vaccinated with doses of improperly stored (Oka/Merck) VARIVAX injection (strength, dose, route and site of administration, lot # and expiry date were unspecified). No concomitant medications were reported. No adverse effect were reported. This is one of several reports from the same source. Additional information has been requested.
Pt was given both doses of covid vaccine but did not have adverse reactions in office. pt waited 30mins for possible side effects.
Within 3 minutes of injection I developed a medicinal, metallic taste in my mouth; tingling in my tongue and on my lips; This is a spontaneous report from a contactable consumer herself. A 76-years-old female patient received first dose bnt162b2 (Solution for injection, Pfizer, Lot number:EL3249) via an unspecified route of administration arm left from 27Jan2021 09:30 at single dose for Covid-19 immunization. Medical history included rheumatoid arthritis, and Hypothyroid. Concomitant medication included adalimumab (HUMIRA), levothyroxine sodium (SYNTHROID), montelukast sodium (SINGULAIR), ezetimibe (ZETIA), rosuvastatin calcium (CRESTOR) and calcium. The patient previously took metronidazole (FLAGYL) and experienced allergy. On 27Jan2021, 09:30 AM, within 3 minutes of injection I developed a medicinal, metallic taste in my mouth. In a few more minutes, tingling in my tongue and on my lips and for both events received treatment Benadryl and extra waiting. The outcome o the events recovered in 2021
Sunday, Feb 21, 2021. Patient told her husband she didn?t feel well and she lay down next to him. She was tossing and looked like she was trying to get up. He was talking to her and she wasn?t answering him. She was having trouble breathing. Took her to the hospital right away at 7:30 pm. They put her into a comma with a respirator. Finally went from emergency room to ICU on Monday. Then on Wednesday they took the respirator out and I spoke to her ? told her we all love her and she could only say hoarsely ?terrible, terrible.? They said she might get moved to regular floor. But then Wednesday night couldn?t breathe again and put the respirator back in. Thursday morning husband had it removed and she died that evening at 10:51 on February 25.
Injection site reaction that migrated to a warm-to-touch, painful area below the deltoid muscle in the subcutaneous tissue. Right arm tenderness. Fever, chills, back ache
She got her vaccine, she wasn't feeling good right there and didn't know what it was going to progress to. She then at 2:00 AM the next morning she rolled out of the bed and fell to the floor and got stuck between the bed and was not able to stand up, and crawled down 14 stairs and then couldn't move.  She could not tell him why she couldn't and she was not able to stand up (large women).  Her husband did not see any signs of stroke.  They called his son and noticed that her face was sagging and he said that it looked like a stroke.  They called the paramedics and they sent her to hospital and she was flown to Clinic and diagnosed with a stroke.  She had surgery and they tried to remove the blood clot and her blood pressure went high and they cut a huge part of her skull to remove the pressure, but not able to remove the clot that he is aware of.  She is in rehab right now, and it's not really showing any signs of promise. She has a lot of stroke symptoms of being combative and she has a blood clot that has moved to her arm as well. She had 6 blood clots on her brain when they went into it, and now has blood clots in each arm. She is aware of her surroundings to some degree and thinks that she is somewhere else and feels like she has wet herself.  Her husband said that the rehab does not look promising.    She is still in the hospital and they are having a meeting tomorrow regarding how long they feel she may be there.  She  has very little headway in rehab.  She cannot move her left side, hand or leg.  She is able to move her right side though. Husband feels it has destroyed her life and it will be a miracle if she comes out of it.
This is a spontaneous report received from a contactable consumer or other non-HCP. A pregnant female patient received the 1st dose of BNT162B2 (Comirnaty, batch/lot# unknown), Mar 2021, single dose, for COVID-19 immunisation. The patient's medical history and concomitant medications not reported. Maternal exposure before pregnancy (patient got the first vaccine last week and found out she is pregnant) onset Mar 2021, with outcome unknown. The patient is expected to deliver baby(s) on Dec 30, 2021. No follow-up attempts possible. Information about batch/lot number cannot be obtained. No further information expected.
Diarrhea, queasy feeling in stomach, migraine headache, body aches, tightness in chest, fatigue and feeling confused
Spiking & receding t103-105, pos strep culture, elevated WBC, erythema nodosa, arthralgia& swelling, 4th day sore throat; APAP & ATB gradually reduced fever for longer periods-suspected vasculitis 21APR; dx kawasaki synd;
triuble breathing,paleness,profuse sweating,dizziness,fast heart rate,trouble talking
Patient departed the clinic to drive home and became dizzy and shakey. Patient felt as though her throat was closing.
Patient reported severe nausea, vertigo and 20 pound weight loss due to symptoms.   Symptoms began day of vaccination (May 1st) and continued until May 19th, 2021.  Patient was bed-ridden for over a week then finally went to urgent care on May 17th.   He was prescribed antihistamine and anti-nausea medication.
Information has been received from a pharmacist concerning a 40 year old male patient who on 15-MAR-2010 was vaccinated SQ with a 0.5 ml dose of MMR II (lot number 664659/0838Y). After vaccination the patient did not feel well and appeared "very pale and pasty". This occurred in the physician's office. There were no lab studies performed. On 15-MAR-2010, the patient had recovered. This is one of several reports from the same source. Additional information has been requested.
PT DEVELOPED A MODERATE LOCAL REACTION WITH REDNESS, HARDNESS AND TENDERNESS AT THE VARICELLA INJECTION SITE.
Fever and erythematous papular rash on torso. Fever resolved with acetaminophen in the ER, rash improved with diphenhydramine but was still present the next day.
Symptoms: Involuntary movements off & on. Not reacting to my speaking to her. Time Course: Reaction lasted 2 minutes total. Treatment: Watched her closely. The next morning the same thing occurred while getting diaper changed. Lasted 30 seconds. Then again in the car for just 4 seconds. Called the doctor and they recommended going to the emergency room as a precaution, so we did.
9/23/04 reported enlarged lymph node on neck; called family doctor. Advised Cipro; client did not take. Swelling resolved. Swelling returned of lymph node. Reported 11/1/04, bilateral neck.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Physician). The reporter is the patient.  A 74-year-old male patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 25Sep2023 as dose 1, single (Batch/Lot number: unknown) at the age of 73 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hyperlipidemia" (unspecified if ongoing); "HBP" (unspecified if ongoing); "Parox AF" (unspecified if ongoing); "Iodine Dye allergy" (unspecified if ongoing), notes: Known allergy. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 2, MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 3 (BOOSTER), MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 4 (BOOSTER), MANUFACTURER UNKNOWN), for COVID-19 immunisation; Covid-19 vaccine (DOSE 5 (BOOSTER), MANUFACTURER UNKNOWN), for COVID-19 immunisation. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Oct2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19 which included Paxlovid from 29Oct2023 to 03Nov2023.  The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.; Sender's Comments: Vaccine efficacy varies from person to person and is affected by many factors. The association between the event vaccine failure (CoVID-19) with the suspect product BNT162B2 OMI XBB.1.5 cannot be fully excluded.,Linked Report(s) : US-PFIZER INC-202300366064 Same patient/reporter, different drug/Event;
no adverse event; VARIVAX had t/e on 16-AUG-2023 and was administered to patient; This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. On 21-AUG-2023, the patient was vaccinated with a 0.5 mL dose of varicella virus vaccine live (oka/merck) (VARIVAX) (lot # reported as W039699) (route not reported) that had a temperature excursion on 16-AUG-2023. The temperature of excursion was 25.8 °C for a time frame of 9 hours 24 minutes. There were no previous excursions. The reported also stated that the freezer units have ice packs in them that never melted during the excursion.  Lot # W039699 is an invalid lot number for varicella virus vaccine live (oka/merck) (VARIVAX).  This is one of several reports received from the same source.; Sender's Comments:  US-009507513-2309USA006884: US-009507513-2309USA009906: US-009507513-2309USA009907: US-009507513-2309USA009908: US-009507513-2309USA009909: US-009507513-2309USA009910: US-009507513-2309USA009911: US-009507513-2309USA009912: US-009507513-2309USA009913: US-009507513-2309USA009914: US-009507513-2309USA009915: US-009507513-2309USA009927: US-009507513-2309USA009928: US-009507513-2309USA009929: US-009507513-2309USA009930:
This spontaneous report as received from a pharmacist refers to a 64 year old female patient with aspirin allergy. On 21-SEP-2013 the patient was vaccinated with ZOSTAVAX lot # J007856, exp: 28-SEP-2014, 0.65 ml, subcutaneous for shingles prevention. The patient had no pertinent medical history or drug allergy. Pharmacist called to report that the daughter of the patient reported that her mother had developed blotchy and log red rashes at the injection site which was also warm to the touch after receiving ZOSTAVAX on 21-SEP-2013. Exact event onset date was unspecified. No treatment was given. No lab test was done. At reporting time, the patient was not recovered from the event. Patient spoke with pharmacist to seek medical attention. Additional information has been requested.
PT VACCINATED ON 03/15 BECAME SYMPTOMATIC AND RAPID ANTIGEN POSITIVE.
No adverse event; Moderna COVID-19 Vaccine administered as part of the primary series to a 17 year old patient that previously received 2 shots from the primary series and 1 booster all three of them from Pfizer; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna COVID-19 Vaccine administered as part of the primary series to a 17 year old patient that previously received 2 shots from the primary series and 1 booster all three of them from Pfizer) and NO ADVERSE EVENT (No adverse event) in a 17-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 055A22A) for COVID-19 prophylaxis.     Patient never had COVID + test or diagnosis.  Patient did not have acute and chronic illnesses at the time of vaccination.  Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (1st dose, Lot number: 31130BA,Expiration date: Dec2021) on 23-Sep-2021, PFIZER BIONTECH COVID-19 VACCINE (2nd dose, Lot number:31076BD, Expiration date: Jan2022) on 15-Oct-2021, PFIZER BIONTECH COVID-19 VACCINE (1st booster dose, Lot no: FL3205 and Expiration date:Feb2022) on 21-Feb-2022. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE, PFIZER BIONTECH COVID-19 VACCINE and PFIZER BIONTECH COVID-19 VACCINE.    On 13-Sep-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Sep-2022, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna COVID-19 Vaccine administered as part of the primary series to a 17 year old patient that previously received 2 shots from the primary series and 1 booster all three of them from Pfizer). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna COVID-19 Vaccine administered as part of the primary series to a 17 year old patient that previously received 2 shots from the primary series and 1 booster all three of them from Pfizer) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna COVID-19 Vaccine administered as part of the primary series to a 17 year old patient that previously received 2 shots from the primary series and 1 booster all three of them from Pfizer).    No concomitant medications were reported. Patient was not given any other vaccines within 1 month prior to Moderna COVID-19 vaccine. No treatment medications were reported.
Pt received vaccine 09/18/09, that night pt reports very swollen inj site along w/ arthralgias along with myalgias. Pt took ibuprofen w/o any resolution of sx. Pt then reported to emloyee health and recieved medrol dose pak with resolution of systems.
Initial report was received from a health care professional on 21 October 2011. A female patient (date of birth and age were not reported) received an injection of FLUZONE (lot number, route, site and date of administration not reported). On 21 October 2011, the patient called the office to report that she developed the flu after receiving FLUZONE. The patient declined to provide further information. Medical history and concomitant medication were reported as unknown. No further information was available at the time of the report. The patient outcome was unknown. Documents held by sender: none.
Redness, warm, tenderness at injection site.  Patient also complained of feeling "woozy" next day. Pt. given Zyrtec.  Redness decreased and better within 2 days after injection.
9:45 headache, extreme fatigue, high BP w/manual cuff (2) 120/92. Monitored, water and crackers given. Observed BP original w/electronic cuff (1) 159/114 P65.
The pt complained of headache, nausea, loose bowel movements, dizziness. Still has headache and dizziness. Injection site red, swollen and burning.